ArticleEuropean heart journal. Quality of care & clinical outcomes2025
Applicability of guideline-informing lipid-lowering clinical trials to contemporary real-world patients with atherosclerotic cardiovascular disease.
Article in European heart journal. Quality of care & clinical outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsLipid-lowering randomized clinical trials (RCTs) inform guideline recommendations for secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, these trials were often conducted decades ago using strict eligibility criteria, which may limit their applicability to today's diverse ASCVD population. This study compared clinical characteristics and long-term outcomes between trial-eligible and ineligible real-world ASCVD patients. METHODS AND
resultsEligibility criteria from eight pivotal lipid-lowering RCTs were applied to patients with coronary artery disease (CAD), cerebrovascular disease (CeVD), and peripheral artery disease (PAD) in the Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease (UCC-SMART) study (2000-2023). The proportion of patients meeting eligibility criteria was determined for each trial. Differences in clinical characteristics between trial-eligible and ineligible patients were assessed, and risks of recurrent cardiovascular (CV) events and all-cause mortality were compared using cumulative incidence curves with 95% confidence intervals, accounting for competing risks. Among 8537 patients with ASCVD (5673 CAD; 2493 CeVD; 1302 PAD), median follow-up was 8.8 years (interquartile range: 4.2-13.9). Trial eligibility ranged from 9 to 85% for CAD, 7 to 42% for CeVD, and 8 to 78% for PAD. Eligibility was generally higher for earlier trials. Trial-eligible and ineligible patients differed in clinical characteristics in most trials, but their risks of recurrent CV events and all-cause mortality were largely comparable.
conclusionEligibility of real-world ASCVD patients for lipid-lowering RCTs varied substantially across trials and ASCVD subtypes. Despite differences in clinical characteristics, trial-eligible and ineligible patients generally had comparable outcomes, suggesting that guideline-informing lipid-lowering trials are broadly representative of contemporary real-world ASCVD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.